Medical Device and Healthcare Industry Trends — 2026-05-31

Top 5 Headlines Today

• Samsung Electronics: To showcase its AI-based connected care ecosystem and new Samsung Health features at VivaTech 2026 (Paris, June 17-20).
• Korean Medical Device Industry: The new KOSDAQ tier system creates favorable conditions for device makers (e.g., Classys) while pressuring traditional biotech drug developers.
• Lunit: Expanding its U.S. subscription-based AI business, hitting 930,000 cumulative SaaS contracts and identifying M&A opportunities in digital pathology.
• MFDS (Ministry of Food and Drug Safety): Celebrated the 1st anniversary (May 26) of its innovation roadmap, which reduced the authorization and review period for biopharmaceuticals to 240 days.
• FDA Deregulation: Lowered barriers for digital health entry by easing regulations on AI Clinical Decision Support (CDS) software and wearable devices.

Key Corporate Trends

Samsung Electronics

• What's Happening: Showcasing AI-based healthcare solutions at the major European tech festival, VivaTech 2026 (June 17-20). New Samsung Health features and wellness partnerships to be unveiled.
• Key Data: Event dates are June 17-20 in Paris.
• Implication: Samsung is positioning wearables and healthcare AI as central pillars of its global marketing, aiming to prove the digital health competitiveness of major Korean firms internationally. The FDA's trend toward easing wearable regulations further boosts market expansion potential.

Lunit

• What's Happening: Pushing for broader adoption of its subscription-based (SaaS) AI diagnostic solutions among U.S. medical institutions, while eyeing growth via the global digital pathology M&A boom.
• Key Data: Surpassed 930,000 cumulative SaaS contracts, focusing on expanding the subscription revenue model in the U.S.
• Implication: The FDA's relaxed stance on AI medical devices is accelerating the U.S. market entry for Korean AI firms like Lunit. The company is developing business diversification strategies aligned with the M&A trend in digital pathology.

Classys

• What's Happening: Benefiting from the KOSDAQ tier system, which favors medical device stocks. Q1 revenue hit 8.72 billion KRW, up 13% year-on-year.
• Key Data: Q1 2026 revenue 8.72 billion KRW (+13% YoY); recorded a 42.7% operating profit margin following the integration of the Brazilian distributor MedSystems.
• Implication: The KOSDAQ reorganization improves capital market access for medical device and healthcare companies. This serves as a prime example of how global distribution network strengthening through M&A leads to revenue growth.

MFDS, Policy, and Regulation

1st Anniversary of K-Bio Innovation Roadmap: Bio-pharmaceutical review period cut to 240 days

• Details: On May 26, the MFDS announced that the "K-Bio Innovation Support Team," launched in 2025, achieved one of the world's shortest review periods (240 days) for biopharmaceuticals.
• Target: Biopharmaceutical developers and medical device manufacturers.
• Timeline: Launched in 2025; results announced on May 26, 2026.
• Industry Impact: Strengthens Korea's competitiveness in global drug and device entry, supporting faster approvals for innovative firms like Lunit and Classys.

Operation of Market Immediate Entry Medical Technology System

• Details: An expedited entry system for innovative medical devices announced by the MFDS and the Ministry of Health and Welfare on Jan 26. Allows clinical entry into hospitals within as little as 80 days.
• Target: Medical devices applying cutting-edge technologies like AI and Big Data.
• Timeline: Launched Jan 26, 2026.
• Industry Impact: Enhances institutional support, allowing Korean developers to reach clinical settings faster and facilitating rapid commercialization for startups.

50% Increase in MFDS Designated Innovative Medical Devices (45 cases in 2025)

• Details: The MFDS designated 45 medical devices utilizing AI and Big Data as "innovative" in 2025, a 50% increase from the previous year.
• Target: Developers of cutting-edge medical devices (AI diagnostics, wearables, digital health).
• Timeline: Designated in 2025; announced Jan 2026.
• Industry Impact: Highlights the accelerated adoption of innovative technologies in the Korean industry, expanding market opportunities for those in government-backed AI and digital sectors.

Digital Health & AI Medical

• FDA Wearable/AI Deregulation: Between Jan 7-9, the FDA significantly reduced regulations on general wearable devices and AI Clinical Decision Support (CDS) software. Low-risk AI health software and non-invasive wearables are increasingly likely to be exempt from medical device regulations, lowering entry barriers for companies like Lunit and Samsung.

• FDA TEMPO Pilot Program: On Dec 5, 2025, the FDA announced the "Technology Enablement for Medical Devices with Meaningful Patient Outcomes (TEMPO)" pilot, supporting early market entry and risk-based regulatory approaches for digital health devices.

• Samsung Health Global Expansion: Samsung will reveal new AI-based features for Samsung Health at VivaTech 2026, centering its global marketing on its wearable and healthcare AI platform.

Global MedTech Context

• FDA Regulatory Shift (Announced in Jan) — Implication: Easing regulatory uncertainty in the U.S. creates entry opportunities for Korean firms like Lunit, Samsung, and Dyne Medical, especially regarding low-risk AI CDS and general wellness functions.

• Global Digital Pathology M&A Boom — Implication: Lunit’s expansion in the U.S. and its M&A strategy signal a rise in international acquisitions for Korean firms, reflecting increased global demand for Korean technology.

• Korean Presence at VivaTech 2026 — Implication: Samsung’s presence in Paris raises the global profile of the Korean health-tech ecosystem, validating K-companies' international competitiveness in AI healthcare and wellness.

Investment, M&A, and Market Trends

• Classys' Acquisition of Brazilian Distributor: The integration of MedSystems resulted in a 42.7% operating margin and 13% revenue growth in Q1 2026, demonstrating the success of overseas distribution network strategies.

Today's Insight

With the introduction of the KOSDAQ tier system and the FDA's regulatory easing, a "dual window of opportunity" has opened for the Korean medical device and healthcare industry. Listed companies like Classys are seeing better capital market access, while AI-healthcare leaders like Lunit and Samsung are accelerating U.S. and European market entry. Supported by the MFDS's 80-day expedited approval process, Korea is poised for a "golden era" of medical devices and AI.

This Week's Checkpoints

• June 17-20: Samsung Electronics' participation in VivaTech 2026 and reveal of its AI healthcare ecosystem.
• FDA: Announcement of participating companies and selection schedule for the TEMPO pilot program.
• KHIDI (Korea Health Industry Development Institute): Investment announcements related to the global expansion of K-Health.

Reader Action Items

• Medical Device Developers: Check the application requirements and procedures for the MFDS "Market Immediate Entry Medical Technology" (80-day expedited approval).
• Investors/M&A Professionals: Monitor the impact of KOSDAQ tier changes on listed medical device companies like Classys for valuation reassessment.
• AI Healthcare Startups: Review the FDA's detailed guidelines on wearable/AI CDS deregulation and adjust U.S. market entry strategies.